CURVEBEAM AI LIMITED (CVB)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CVB

CVB - CURVEBEAM AI LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : NONE
Debt/EBITDA: -0.75
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.13

11 Sep
2025

-0.005

OPEN

$0.13

-3.70%

HIGH

$0.13

42,164

LOW

$0.13

TARGET
$0.15 15.4% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
CVB: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 7.9 - 11.4 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202320242025
EPS Basic xxxxxx-4.5
DPS All xxxxxx0.0
Sales/Revenue xxxxxx12.1 M
Book Value Per Share xxxxxx9.1
Net Operating Cash Flow xxxxxx-11.2 M
Net Profit Margin xxxxxx-139.24 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202320242025
Return on Capital Employed xxxxxx-45.50 %
Return on Invested Capital xxxxxx-32.20 %
Return on Assets xxxxxx-27.10 %
Return on Equity xxxxxx-45.50 %
Return on Total Capital xxxxxx-35.72 %
Free Cash Flow ex dividends xxxxxx-11.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202320242025
Short-Term Debt xxxxxx2 M
Long Term Debt xxxxxx16 M
Total Debt xxxxxx18 M
Goodwill - Gross xxxxxx20 M
Cash & Equivalents - Generic xxxxxx5 M
Price To Book Value xxxxxx0.85

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202320242025
Capex xxxxxx0.5 M
Capex % of Sales xxxxxx4.04 %
Cost of Goods Sold xxxxxx24 M
Selling, General & Admin. Exp & Other xxxxxx8 M
Research & Development xxxxxx0 M
Investments - Total xxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

04/09/2025

3

Downgrade to Hold from Buy

$0.15

15.38%

Bell Potter downgrades Curvebeam AI to a Speculative Hold from Speculative Buy with a target set at 15c from 18c post FY25 results.

The company took 26 new orders for devices in FY25 compared to 22 in the prior year, and the analyst had estimated around 20, which drove revenue to $12.1m and gross profit of $6.7m. The adjusted earnings (EBITDA) loss of -$11.1m was as expected.

Further device sales are awaiting the validation of the HiRise device by Stryker for use with the Mako robotic surgery device. The analyst anticipates validation in 4Q26.

Bell Potter downgrades its FY26 revenue forecasts in line with levels achieved in FY25. Management offered no guidance on Mako validation completion, hence the downgrade in rating.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -11.40 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -9.40 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

CVB STOCK CHART

FNArena News on CVB

1
Weekly Ratings, Targets, Forecast Changes – 05-09-25

Sep 08 2025 - Weekly Reports
2
FNArena Corporate Results Monitor – 04-09-2025

Sep 04 2025 - Australia
3
FNArena Corporate Results Monitor – 03-03-2025

Mar 03 2025 - Australia
4
FNArena Corporate Results Monitor – 06-09-2024

Sep 06 2024 - Australia

Latest Medical Equipment & Devices News

1
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia
2
ResMed’s New Level Of Support

Jul 29 2025 - Technicals
3
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025 - Australia
4
Cochlear Downgrades Ahead Of New Launches

Jun 19 2025 - Australia
5
Fisher & Paykel Healthcare’s Tariffs Annoyance

Jun 04 2025 - Australia
6
ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025 - Australia
7
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
8
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
9
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
10
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia